Safety Assessment of
PEG-150 Pentaerythrityl Tetrastearate as Used in Cosmetics

Status: Tentative Report for Panel Review
Release Date: March 28, 2014
Panel Date: June 9-10, 2014

All interested persons are provided 60 days from the above date to comment on this Tentative Report and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. Lillian J. Gill.

The 2014 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; Ronald A. Hill, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This report was prepared by Wilbur Johnson, Jr., M.S., Senior Scientific Analyst and Bart Heldreth, Ph.D., Chemist.
# Table of Contents

INTRODUCTION .......................................................................................................................... 1  
CHEMISTRY ................................................................................................................................. 1  
  DEFINITION AND STRUCTURE .......................................................................................... 1  
  PHYSICAL AND CHEMICAL PROPERTIES ....................................................................... 1  
  METHOD OF MANUFACTURE ............................................................................................... 1  
  COMPOSITION/IMPURITIES ................................................................................................. 2  
USE ........................................................................................................................................ 2  
  COSMETIC .......................................................................................................................... 2  
TOXICOKINETICS ...................................................................................................................... 2  
TOXICOLOGY ............................................................................................................................... 2  
  ACUTE TOXICITY .................................................................................................................. 2  
    Oral ....................................................................................................................................... 2  
  REPEATED DOSE TOXICITY ................................................................................................. 2  
  OCULAR IRRITATION ........................................................................................................... 2  
  SKIN IRRITATION AND SKIN SENSITIZATION ................................................................. 3  
REPRODUCTIVE AND DEVELOPMENTAL TOXICITY ................................................................. 3  
GENOTOXICITY .......................................................................................................................... 3  
  In Vitro Assays ..................................................................................................................... 3  
CARCINOGENICITY ..................................................................................................................... 4  
SUMMARY ................................................................................................................................ 4  
DISCUSSION ............................................................................................................................... 4  
CONCLUSION ............................................................................................................................. 5
ABSTRACT: PEG-150 pentaerythritol tetrastearate functions as a viscosity increasing agent-aqueous in cosmetic products, and is being used at concentrations up to 5%. Given the chemical structure (large molecule), skin penetration is not likely. The available toxicity data and the low ingredient use concentrations, suggest that systemic toxicity would not be likely if percutaneous absorption were to occur. Additionally, the negative human repeated insult patch test data on the undiluted ingredient were deemed sufficient for evaluating skin irritation and sensitization potential. The Expert Panel concluded that PEG-150 pentaerythritol tetrastearate is safe in the present practices of use and concentration in cosmetics.

INTRODUCTION

This report presents information relevant to evaluating the safety of PEG-150 pentaerythritol tetrastearate as used in cosmetics. This ingredient functions as a viscosity increasing agent-aqueous in cosmetic products.

CHEMISTRY

Definition and Structure

PEG-150 pentaerythritol tetrastearate (CAS No. 130249-48-8) is the tetraester of stearic acid and a polyethylene glycol ether of pentaerythritol with an average of 150 moles of ethylene oxide, and conforms to the molecular structure shown in figure 1:

![Figure 1. PEG-150 pentaerythritol tetrastearate (wherein the sum of all instances of n is equal to 150)](image)

Physical and Chemical Properties

PEG-150 pentaerythritol tetrastearate (Crothix®) is slightly soluble in water, has a melting point of 45°C, and has a pH range of 5.5 to 7.5 (1% solution). The specifications for another PEG-150 pentaerythritol tetrastearate trade name material, Crothix-PA-(MH), are included in Table 1.

Method of Manufacture

PEG-150 pentaerythritol tetrastearate is produced by reacting pentaerythritol with ethylene oxide until the equivalent of 150 moles of ethylene oxide are added. The reaction is run under controlled conditions to ensure that moisture is very low during the ethylene oxide reaction stage, to ensure minimal formation of free PEG. The resulting ethoxylated pentaerythritol is esterified with 4 moles of stearic acid to form the tetraester.
Composition/Impurities

Based on the acid value specification of 5.0 mg KOH/g for PEG-150 pentaerythrityl tetrastearate (Crothix-PA-(MH)) in Table 1, the amount of free stearic acid present would be less than 2.5%. In addition to the values included in Table 1, the specifications for this trade name material include the following: moisture content (1%), ethylene oxide (1 ppm), and 1,4-dioxane (5 ppm).

USE

Cosmetic

PEG-150 pentaerythrityl tetrastearate functions as a viscosity increasing agent-aqueous in cosmetic products. Information on the use of this ingredient as a function of product type was supplied to the Food and Drug Administration (FDA) by industry as part of the Voluntary Cosmetic Registration Program (VCRP) in 2014. These data indicate that PEG-150 pentaerythrityl tetrastearate is being used in rinse-off and in leave-on products, with the majority of uses in rinse-off products. The Personal Care Products Council conducted a survey of ingredient use concentrations in 2013-2014, and a maximum use concentration of 5% (in hair dyes and colors) was reported for PEG-150 pentaerythrityl tetrastearate. The maximum reported use concentrations for rinse-off and leave-on products were 5% (hair dyes and colors) and 1.8% (tonics, dressings, and other hair grooming aids), respectively. Ingredient frequency-of-use and use concentration data are included in Table 2.

Cosmetic products containing PEG-150 pentaerythrityl tetrastearate may be applied to the skin and hair, and may come in contact with mucous membranes, or, incidentally, these products may come in contact with the eyes. Products containing this ingredient may be applied as frequently as several times per day and may come in contact with the skin or hair for variable periods following application. Daily or occasional use may extend over many years.

TOXICOKINETICS

Data on the absorption, distribution, metabolism, and excretion of PEG-150 pentaerythrityl tetrastearate were not found in the published literature, nor were unpublished data provided.

TOXICOLOGY

Acute Toxicity

Oral

The acute oral toxicity of a 25% gravimetric [sic; presumed meaning is 25% w/w], aqueous suspension of PEG-150 pentaerythrityl tetrastearate was evaluated using 10 Wistar albino rats (5 males, 5 females; 6 to 9 weeks old). Each animal received a single oral dose of 5 g/kg body weight. Dosing was followed by a 14-day observation period, and gross necropsy was performed. None of the animals died, and it was concluded that the test substance did not induce toxicity.

Repeated Dose Toxicity

Data on the repeated dose toxicity of PEG-150 pentaerythrityl tetrastearate were not found in the published literature, nor were unpublished data provided.

Ocular Irritation

The ocular irritation potential of undiluted PEG-150 pentaerythrityl tetrastearate was evaluated using 6 New Zealand white rabbits. The test substance (0.1 ml) was instilled into one eye of each animal, and the untreated contralateral eye served as the control. Eyes were not rinsed after test substance administration. Treated eyes were observed for corneal opacity, iritis, and conjunctivitis at 24 h, 48 h, and 72 h post-instillation. The test substance did not induce ocular irritation.
Skin Irritation and Skin Sensitization

Animal

The skin irritation potential of undiluted PEG-150 pentaerythrityl tetrastearate was studied using 6 New Zealand white rabbits (3 months old). The test substance (0.5 ml) was applied to 2 sites (1 abraded, 1 intact) on opposite sides of the vertebral column. Application sites were occluded for 24 h, and then evaluated for erythema, edema, and other effects at 24 h and 72 h post-application. The test substance did not cause primary skin irritation (primary irritation index [PII] = 2.65).

Human

The skin irritation and sensitization potential of undiluted PEG-150 pentaerythrityl tetrastearate was studied using 53 subjects (18 to 71 years old). A semi-occlusive patch (1” x 1” gauze patch) containing 0.2 g of the test substance was applied to the upper back, between the scapulae, 3 times per week for a total of ten 24-h induction applications. Following a 2-week non-treatment period, a 24-h challenge patch was applied to the original site and to a new site. Reactions were scored at 24 h and 48 h post-application. There was no evidence of a visible reaction in any of the subjects, and it was concluded that the test substance did not have skin irritation or sensitization potential in this study.

In Vitro

The skin irritation potential of PEG-150 pentaerythrityl tetrastearate (25% in distilled water) was evaluated using the MatTek Corporation EpiDerm in vitro toxicity testing system. This skin model consists of normal, human-derived epidermal keratinocytes (NHEK), cultured to form a multilayered, highly differentiated model of the human epidermis. When used with the recommended cell metabolism assay, EpiDerm can provide toxicological profiles. This procedure involves 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT), a yellow, water-soluble tetrazolium salt that is reduced by succinate dehydrogenase to a purple formazan derivative in the mitochondria of viable cells. Substances that damage this mitochondrial enzyme inhibit reduction of the tetrazolium salt. Therefore, the amount of MTT reduced by a culture is proportional to the number of viable cells. Data from this assay were presented in the form of a plot (semi-log scale) of percent viabilities versus the dosing times, and the time at which the percent viability would be 50% (ET-50) for the test substance was estimated. The ET-50 for 25% PEG-150 pentaerythrityl tetrastearate was > 24 h, meaning that the test substance is expected to be non-irritating when dosed in vivo.

In another in vitro test known as the SKINTEX test, 10% PEG-150 pentaerythrityl tetrastearate was classified as non-irritating. SKINTEX is defined as an in vitro method for assessing skin irritation that uses pumpkin rind to mimic the reaction of a foreign substance to human skin. Details relating to the test procedure were not provided.

REPRODUCTIVE AND DEVELOPMENTAL TOXICITY

Data on the reproductive or developmental toxicity of PEG-150 pentaerythrityl tetrastearate were not found in the published literature, nor were unpublished data provided.

GENOTOXICITY

In Vitro Assays

The genotoxicity of PEG-150 pentaerythrityl tetrastearate was evaluated in the Ames test using the following bacterial strains, with and without metabolic activation, at doses up to 5,000 µg/plate: Salmonella typhimurium strains TA98, TA100, TA1535, and TA1537 and Escherichia coli strain WP2uvrA. The following positive controls were used: 2-aminoanthracene, 2-nitrofluorene, sodium azide, 9-aminoacridine, and methyl methanesulfonate. No appreciable toxicity
was induced by the test substance, and there was no evidence of genotoxicity, with or without metabolic activation, over the range of doses tested. All positive controls were genotoxic.

In another assay (Ames test), the genotoxicity of PEG-150 pentaerythrityl tetrastearate (1 g in DMSO) was evaluated with metabolic activation using the following *Salmonella typhimurium* strains: TA98, TA100, TA1535, TA1537, and TA1538. The following positive controls were used: paradimethylaminobenzene disodium sulfonate, sodium azide, 2-nitrofluorene, and 2-aminofluorene. The test substance was not considered genotoxic, whereas all positive controls exhibited their expected genotoxicities.

**CARCINOGENICITY**

Data on the carcinogenicity of PEG-150 pentaerythrityl tetrastearate were not found in the published literature, nor were unpublished data provided.

**SUMMARY**

PEG-150 pentaerythrityl tetrastearate functions as a viscosity increasing agent-aqueous in cosmetic products. Frequency-of-use data provided by the Food and Drug Administration indicate that this ingredient is being used in rinse-off and in leave-on products, with the majority of uses in rinse-off products. The Personal Care Products Council conducted a survey of ingredient use concentrations in 2013-2014, and a maximum use concentration of 5% (in hair dyes and colors, rinse-off products) was reported for PEG-150 pentaerythrityl tetrastearate. The maximum reported use concentration for leave-on products was 1.8% (tonics, dressings, and other hair grooming aids).

PEG-150 pentaerythrityl tetrastearate is produced by reacting pentaerythritol with ethylene oxide until the equivalent of 150 moles of ethylene oxide are added. The reaction is run under controlled conditions to ensure that moisture is very low during the ethylene oxide reaction stage, to ensure minimal formation of free PEG. The resulting ethoxylated pentaerythritol is esterified with 4 moles of stearic acid to form the tetraester. Additionally, the specifications for impurities limit ethylene oxide and 1,4-dioxane to 1 ppm and 5 ppm, respectively.

A 25% gravimetric [sic; presumed meaning is 25% w/w], aqueous suspension of PEG-150 pentaerythrityl tetrastearate (dose = 5 g/kg) was non-toxic in an acute oral toxicity study involving albino rats.

In an ocular irritation study involving rabbits, undiluted PEG-150 pentaerythrityl tetrastearate was classified as a non-irritant. Undiluted PEG-150 pentaerythrityl tetrastearate also did not cause primary skin irritation (abraded or intact skin) in rabbits. *In vitro* tests evaluating the skin irritation potential of PEG-150 pentaerythrityl tetrastearate at concentrations of 25% aqueous and 10% were also negative. Neither skin irritation nor sensitization was observed in human repeated insult patch tests in which subjects were patch-tested with undiluted PEG-150 pentaerythrityl tetrastearate or a 25% aqueous solution of this ingredient.

PEG-150 pentaerythrityl tetrastearate was not genotoxic in the Ames test using the following *Salmonella typhimurium* strains, with or without metabolic activation: TA98, TA100, TA1535, TA1537, and TA1538.

Data on the toxicokinetics, repeated dose toxicity, carcinogenicity, or reproductive and developmental toxicity of PEG-150 pentaerythrityl tetrastearate were not found in the published literature.

**DISCUSSION**

Current use concentration data indicate that the maximum reported use concentrations for PEG-150 pentaerythrityl tetrastearate in rinse-off and leave on products were 5% and 1.8%, respectively. Because the method of manufacture ensures minimal formation of free PEG and the specifications for impurities limit ethylene oxide and 1,4-dioxane to 1 ppm and 5 ppm, respectively, the Panel agreed that concerns about these impurities in the finished cosmetic product are not warranted. Furthermore, after considering the large size of this molecule, based on the chemical structure, the Panel agreed that percutaneous absorption is not expected. The absence of the potential for percutaneous absorption and the negative
genotoxicity and skin irritation and sensitization studies provided the Panel with a sufficient basis for assessing the safety of PEG-150 pentaerythritol tetrastearate, when used as a viscosity increasing agent in cosmetic products.

It is possible that PEG-150 pentaerythritol tetrastearate may be used in products that are sprayed (highest maximum use concentration = 1.8%, in tonics, dressings, and other hair grooming aids) and in face and neck powders (highest maximum use concentration = 1.4%). Though use in these types of products has not been confirmed, the Panel discussed the issue of incidental inhalation exposure from propellant and pump sprays and powders, and considered pertinent data indicating that incidental inhalation exposures to this ingredient in such cosmetic products would not cause adverse health effects. The data considered include data characterizing the potential for this ingredient to cause acute oral toxicity and ocular or dermal irritation or sensitization. The Panel noted that 95% – 99% of droplets/particles produced in cosmetic aerosols would not be respirable to any appreciable amount. Coupled with the small actual exposure in the breathing zone and the concentrations at which the ingredients are used, the available information indicates that incidental inhalation would not be a significant route of exposure that might lead to local respiratory or systemic effects. A detailed discussion and summary of the Panel’s approach to evaluating incidental inhalation exposures to ingredients in cosmetic products is available at http://www.cir-safety.org/cir-findings.

CONCLUSION

The CIR Expert Panel concluded that PEG-150 pentaerythritol tetrastearate is safe in the present practices of use and concentration in cosmetics, as described in this safety assessment.
### Table 1. Specifications for PEG-150 Pentaerythritol Tetraesterate

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Form (at 25°C)</td>
<td>Pastilles (white to off-white)</td>
</tr>
<tr>
<td>Odor</td>
<td>Characteristic</td>
</tr>
<tr>
<td>Acid Value</td>
<td>5 mg KOH/g</td>
</tr>
<tr>
<td>Hydroxyl Value</td>
<td>10 mg KOH/g</td>
</tr>
</tbody>
</table>

### Table 2. Frequency and Concentration of Use According to Duration and Type of Exposure for PEG-150 Pentaerythritol Tetraesterate

<table>
<thead>
<tr>
<th>Total/Conc. Range</th>
<th># of Uses</th>
<th>Conc. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>510</td>
<td>0.0005-5</td>
<td></td>
</tr>
</tbody>
</table>

**Duration of Use**

<table>
<thead>
<tr>
<th>Exposure Type</th>
<th># of Uses</th>
<th>Conc. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leave-On</td>
<td>20</td>
<td>0.037-1.8</td>
</tr>
<tr>
<td>Rinse off</td>
<td>460</td>
<td>0.0005-5</td>
</tr>
<tr>
<td>Diluted for (bath) Use</td>
<td>29</td>
<td>0.9-1.2</td>
</tr>
</tbody>
</table>

**Exposure Type**

<table>
<thead>
<tr>
<th>Exposure Type</th>
<th># of Uses</th>
<th>Conc. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye Area</td>
<td>1</td>
<td>NR</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Incidental Inhalation - Sprays</td>
<td>8</td>
<td>0.15-1.8*</td>
</tr>
<tr>
<td>Incidental Inhalation - Powders</td>
<td>1</td>
<td>0.037-1.4**</td>
</tr>
<tr>
<td>Dermal Contact</td>
<td>443</td>
<td>0.0005-4</td>
</tr>
<tr>
<td>Deodorant (underarm)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Hair - Non-Coloring</td>
<td>65</td>
<td>1-3</td>
</tr>
<tr>
<td>Hair-Coloring</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Nail</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Mucous Membrane</td>
<td>408</td>
<td>0.0005-2.7</td>
</tr>
<tr>
<td>Baby Products</td>
<td>5</td>
<td>NR</td>
</tr>
</tbody>
</table>

NR = Not Reported; NS = Not Surveyed; Totals = Rinse-off + Leave-on Product Uses.

*It is possible that these products may be sprays, but it is not specified whether the reported uses are sprays.

**It is possible that these products may be powders, but it is not specified whether or not the reported uses are powders.

Note: Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure type uses may not equal the total uses.
References


